Wegovy Medicare Coverage: What Part D Pays For

——————————————————————————–

The conversation about Wegovy Medicare coverage has shifted a great deal in the past few years. What was once a flat “no” for every Medicare beneficiary is now a qualified “it depends” — coverage may be possible for patients who meet specific cardiovascular criteria, and, starting mid-2026, a separate short-term demonstration adds a limited weight-loss pathway. This guide explains what Medicare Part D can and cannot pay for in 2026, who may qualify, how the out-of-pocket cap interacts with Wegovy, what the new Medicare GLP-1 Bridge does, and what to do if your plan denies a prior authorization. Coverage rules vary by plan and can change, so treat this as background and confirm the details with your specific plan.

How Medicare Part D Traditionally Treated Weight-Loss Drugs

Medicare Part D — the prescription drug benefit added to Medicare in 2003 — excludes several drug categories from required coverage. Among them are drugs “used for weight loss.” This was a statutory decision made by Congress, not a clinical judgment by Medicare. For roughly two decades it meant that Wegovy, Saxenda, Qsymia, and phentermine were generally not covered by Medicare when prescribed purely for weight loss, regardless of patient need.

The Centers for Medicare and Medicaid Services has interpreted this exclusion strictly. The key nuance: when a medication earns a separate, non-weight-loss FDA indication, the weight-loss exclusion no longer blocks coverage for that other use. That technical point became Wegovy’s path into Medicare coverage.

The 2024 Cardiovascular Indication Change

In March 2024, the FDA approved Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight. The approval was based on the SELECT trial, a large outcomes study that reported roughly a 20% reduction in major adverse cardiovascular events in the trial population. You can read the results in the New England Journal of Medicine publication of SELECT.

Following that approval, CMS indicated that Wegovy prescribed for cardiovascular risk reduction could be covered by Part D plans, because that use is not classified as weight loss alone. Individual Part D plans began adding Wegovy to their formularies under this indication, though coverage, tier placement, and restrictions differ from plan to plan.

Who May Qualify for Medicare Wegovy Coverage

To have coverage considered under the cardiovascular indication, a patient generally needs all of the following: enrollment in a Medicare Part D plan or a Medicare Advantage plan with drug coverage; established cardiovascular disease (such as a documented prior heart attack, prior stroke, symptomatic peripheral artery disease, or coronary artery disease); and either obesity (BMI 30 or higher) or overweight (BMI 27–29.9). Because plans set their own criteria within CMS rules, verify the exact requirements with your plan.

The cardiovascular-disease documentation is the crucial part. Patients with only hypertension, high cholesterol, or diabetes — but no history of a major cardiovascular event or established coronary disease — typically do not qualify under this indication. Your prescribing clinician must be willing to document the qualifying diagnosis in your medical record and on the prior authorization form.

How Prior Authorization Works

Prior authorization is required for Wegovy Medicare prescriptions in virtually all Part D plans. The process starts when your prescriber submits the PA request through the plan’s electronic portal or by fax. Required documentation typically includes the ICD-10 code for your cardiovascular diagnosis, a BMI calculation, and a clinical statement tying Wegovy to cardiovascular risk reduction rather than weight loss alone.

Under CMS rules, plans generally must decide a standard PA request within 72 hours and an expedited request within 24 hours. If approved, the plan specifies any quantity limits and refill rules. If denied, you receive a written explanation and information about how to appeal.

The 2026 Part D Out-of-Pocket Cap

One of the most significant recent changes for Medicare beneficiaries is the annual out-of-pocket cap on Part D spending. The cap took effect in 2025 at $2,000 and, indexed for inflation, is $2,100 in 2026. Once your out-of-pocket spending on covered Part D drugs reaches that amount in a calendar year, you enter catastrophic coverage and your plan pays 100% of the cost of covered medications for the rest of the year.

For a Wegovy patient who qualifies under the cardiovascular indication, this cap can be meaningful: it limits total yearly exposure for covered drugs. The Medicare Prescription Payment Plan can also let you spread your out-of-pocket costs evenly across the year instead of paying large amounts at the pharmacy counter. Note the important caveat below — the separate GLP-1 Bridge copay does not count toward this cap.

New for 2026: The Medicare GLP-1 Bridge Demonstration

In 2025, CMS declined to finalize a Biden-era proposal that would have required Medicare and Medicaid to cover anti-obesity drugs; that decision, published in April 2025, means there is still no mandate for Part D to cover Wegovy for weight loss alone. Instead, CMS created a separate, voluntary Medicare GLP-1 Bridge demonstration that runs from July 1, 2026 through December 31, 2027.

Under the Bridge, eligible beneficiaries can access certain GLP-1 drugs — including Wegovy — used for weight reduction and weight maintenance for a flat copay of about $50 per month. Several important limits apply: the Bridge operates outside the standard Part D benefit, so the $50 copay does not count toward your deductible or the $2,100 out-of-pocket cap; Extra Help (the Part D low-income subsidy) cannot be applied to it; and it is time-limited to the demonstration period. Part D plans do not have to opt in for beneficiaries to access the Bridge. Because the program is new and its details and participants can change, confirm current eligibility and terms through CMS or your plan before relying on it.

Medicare Advantage vs Standalone Part D

Medicare Advantage (Part C) plans with drug coverage and standalone Medicare Part D plans both operate under the Part D framework, and each sets its own formulary within CMS rules. In 2026, many plans include Wegovy on formulary for patients meeting the cardiovascular indication, though copay tiers and restrictions vary. During Medicare Open Enrollment (October 15 to December 7), you can compare plans with the Medicare.gov plan finder — enter “Wegovy” in the drug list to see which plans cover it, at what cost-sharing tier, and with what restrictions. Related: our full Medicare Wegovy coverage breakdown.

What to Do If Denied

Medicare has a five-level appeals process. Level one is a redetermination by the Part D plan itself, which must be requested within 60 days of the denial. Level two is reconsideration by an independent review entity. Higher levels include an Administrative Law Judge hearing, the Medicare Appeals Council, and federal court review.

Many appeals succeed at level one or two with stronger clinical documentation. Work with your prescriber to gather the best evidence of your cardiovascular disease — hospital discharge summaries, cardiology consultation notes, imaging reports, and stress-test results. A clear, well-supported appeal generally fares better than a bare-bones resubmission.

Frequently Asked Questions

Does every Medicare Part D plan cover Wegovy?

No. Plans have discretion in formulary design. Many major national Part D plans added Wegovy for the cardiovascular indication in 2024–2025, but specific coverage and tier placement vary. Check your plan’s formulary or the Medicare.gov plan finder, ideally during open enrollment.

Can I get Wegovy covered by Medicare if I only want weight loss?

Not through standard Part D. By statute, Part D cannot cover a drug used for weight loss alone, so standard coverage requires the cardiovascular indication with documented cardiovascular disease. The separate GLP-1 Bridge demonstration (July 2026 through 2027) does offer a roughly $50/month weight-loss pathway, but it sits outside standard Part D and has its own limits.

How much does Wegovy cost under Medicare in 2026?

It depends on the pathway. Under Part D for the cardiovascular indication, monthly cost-sharing varies by plan and counts toward the $2,100 out-of-pocket cap. Under the GLP-1 Bridge for weight loss, the copay is about $50 per month, but it does not count toward the cap and cannot use Extra Help. Confirm your exact costs with your plan.

What if my Medicare plan denies my Wegovy prior authorization?

Request the written denial and review the reason. Work with your prescriber to strengthen the clinical documentation and file a redetermination within 60 days. Appeals often succeed at the first or second level with additional evidence of cardiovascular disease.

Does Original Medicare (without Part D) cover Wegovy?

No. Original Medicare Parts A and B do not include outpatient prescription drug coverage. To have any possibility of Wegovy coverage, you generally need Part D or a Medicare Advantage plan with drug coverage. See what insurance covers Wegovy for weight loss.

Your Next Step With Wegovy and Medicare

Check your current Part D or Medicare Advantage plan’s formulary for Wegovy, either through your plan’s member portal or Medicare.gov. If you have a history of cardiovascular disease and a BMI of 27 or higher, discuss eligibility with your prescribing clinician and ask them to submit a prior authorization with full documentation. If your interest is weight loss and you do not meet the cardiovascular criteria, ask whether the GLP-1 Bridge demonstration is an option for you during its 2026–2027 window.

Our healthcare policy pillar and our Wegovy insurance coverage guide cover broader context on public and private insurance rules. Medicare’s treatment of Wegovy is still evolving — staying current with your plan’s specific rules is essential to actually accessing coverage.